Single User License
INR 17045
Site License
INR 34090
Corporate User License
INR 51135

Service Tax Additional

select a format
Price

Single User License
USD 250
Site License
USD 500
Corporate User License
USD 750

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Johnson and Johnson (JNJ)-Pharmaceuticals and Healthcare-Deals and Alliances Profile

Johnson and Johnson (JNJ)-Pharmaceuticals and Healthcare-Deals and Alliances Profile


  Request for Sample Report

Executive Summary

Johnson & Johnson (J&J) is a holding company that manufactures and sells a broad range of products in pharmaceutical, consumer and medical fields. Its product offerings include drugs to treat immune disorders, neurological diseases, cancer, cardiovascular problems and metabolism disorders; medical products used in orthopedics, surgery, cardiovascular, diabetes care and vision care fields; and consumer products comprising health and personal care products in beauty, skin care, nutritional, oral care, baby care, women's health and over-the-counter, and wellness and prevention categories. It has research facilities in the US, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the UK. The company conducts its operations through subsidiaries the world over. J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 2

List of Tables 11

List of Figures 19

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 20

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 21

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 23

Johnson & Johnson, Medical Devices Deals, 2010 to YTD 2016 25

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 27

Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 60

Asset Purchase 60

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 60

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 62

J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 64

Venture Financing 66

V-Wave Raises USD28 Million in Venture Financing 66

Lodo Therapeutics Raises USD17 Million in Series A Financing 68

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 70

Petra Pharma Raises USD48 Million in Series A Financing 72

Navitor Pharma Raises USD33 Million in Series B Financing 74

First Aid Shot Therapy Raises USD24 Million in Series C Financing 76

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 78

Asceneuron Raises USD30.6 Million in Series A Financing 79

Merus Raises Funds through First Tranche of Series C Financing 81

Alligator Bioscience to Raise Funds through Venture Financing 84

Protagonist Therapeutics Raises USD40 Million in Series C Financing 85

NeuWave Medical Raises USD25 Million in Series C Financing 87

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 89

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 91

La Lumiere Raises USD20 Million in Series B Venture Financing 93

Tetra Discovery Raises Funds through Venture Financing 94

Inivata Raises USD6.5 Million in Venture Financing 95

Inviata Raises USD6.5 Million in Venture Financing 97

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 98

Ascelegen Therapeutics Raises Funds through Venture Financing 100

Padlock Therapeutics Raises Funds through Series A Financing 101

Navitor Pharma Raises USD24 Million in Series A Financing 102

Aduro BioTech Raises USD55 Million in Series C Financing 104

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 106

Assembly Pharma Raises Funds Through Seed Financing 107

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 109

Covagen Raises USD 50.3 Million In Series B Financing 111

Novira Therapeutics Raises USD 28 Million In Series A Financing 113

SutroVax Raises Funds Through Initial Financing Round 115

TopiVert Raises USD28 Million in Venture Financing 116

TopiVert Raises USD 7.4 Million In Venture Financing 118

Pulmocide Raises USD 27.4 Million In Series A Financing 120

Biocartis Raises USD 40.5 Million In Series E Financing 122

Merus Raises USD 42 Million In Extended Series B Financing 124

Rodin Therapeutics Raises Funds Through Seed Financing 126

Vedanta Biosciences Raises Funds Through Venture Financing 127

XO1 Raises USD11 Million in Venture Financing 128

X01 Raises USD 11 Million In Series A Financing 129

Aquinox Pharma Raises USD 18 Million In Series C Financing 130

Biocartis Raises USD 44.7 Million In Series D Financing 132

Genocea Biosciences Raises USD 30 Million In Series C Financing 134

Aragon Pharma Raises USD 50 Million In Series D Financing 137

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 138

Celladon Raises Additional USD 10 Million In Series D Financing 140

Aragon Pharma Raises USD 42 Million In Series C Financing 143

Biocartis Secures USD 96 Million In Series C Financing Round 144

Novira Therapeutics Secures USD 1 Million In Second Round Of Seed Financing 146

Spinal Modulation Secures USD 30 Million In Series D Financing 148

Genocea Biosciences Secures USD 35 Million In Series B Venture Financing 150

PhaseBio Pharma Secures USD 15 Million In The Second Tranche Of Series B Financing Round 153

Covagen Secures USD 6.28 Million In Series A Financing Round 155

Syntaxin Secures USD 29 Million In Series C Financing Round 157

Corimmun Secures USD 10.35 Million In Second Round Of Financing 160

Aquinox Pharma Raises USD 25 Million In Series B Financing 162

Aragon Pharma Raises USD 22 Million In Series B Financing 164

Biocartis Secures USD 41.3 Million In Series B Financing Round 165

Private Equity 167

Water Street Healthcare Partners Acquires OraPharma 167

Partnerships 169

Janssen Amends Licensing Agreement with Gilead for STR 169

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 170

Kuros Biosurgery Enters Into Licensing Agreement With Ethicon 172

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 173

Amyris Enters into Research Agreement with Janssen Biotech 174

Janssen Research & Development Enters into Agreement with Genentech 175

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 176

DiamiR Enters into Research Agreement with Janssen Pharma 177

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 178

Janssen Biotech Enters into Agreement with HUB foundation 179

Janssen Pharma Enters into Agreement with University of Pennsylvania 180

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 181

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 182

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 183

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 184

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 185

Janssen Pharma Enters into Agreement with University of California, San Diego 186

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 187

Johnson & Johnson Consumer Enters into Agreement with BioMed X 188

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 189

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 190

Janssen Biotech Enters into Agreement with Eureka Therapeutics 191

Intrexon Enters into Research Agreement with Janssen Pharma 192

Cypralis Enters into Research Agreement with Janssen Pharma 193

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 194

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 195

Nuevolution Enters into Discovery Agreement with Janssen Biotech 196

enGene Enters into Agreement with Janssen Biotech 197

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 198

Johnson & Johnson-Key Competitors 564

Key Employees 565

Locations And Subsidiaries 567

Head Office 567

Other Locations & Subsidiaries 567

Appendix 588

Methodology 588

About GlobalData 588

Contact Us 588

Disclaimer 588

List of Figures

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 20

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 21

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 23

Johnson & Johnson, Medical Devices Deals, 2010 to YTD 2016 25

List of Tables

Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 20

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 21

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 22

Johnson & Johnson, Deals By Therapy Area, 2010 to YTD 2016 23

Johnson & Johnson, Medical Devices Deals, 2010 to YTD 2016 25

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 27

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 60

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 62

J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 64

V-Wave Raises USD28 Million in Venture Financing 66

Lodo Therapeutics Raises USD17 Million in Series A Financing 68

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 70

Petra Pharma Raises USD48 Million in Series A Financing 72

Navitor Pharma Raises USD33 Million in Series B Financing 74

First Aid Shot Therapy Raises USD24 Million in Series C Financing 76

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 78

Asceneuron Raises USD30.6 Million in Series A Financing 79

Merus Raises Funds through First Tranche of Series C Financing 81

Alligator Bioscience to Raise Funds through Venture Financing 84

Protagonist Therapeutics Raises USD40 Million in Series C Financing 85

NeuWave Medical Raises USD25 Million in Series C Financing 87

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 89

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 91

La Lumiere Raises USD20 Million in Series B Venture Financing 93

Tetra Discovery Raises Funds through Venture Financing 94

Inivata Raises USD6.5 Million in Venture Financing 95

Inviata Raises USD6.5 Million in Venture Financing 97

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 98

Ascelegen Therapeutics Raises Funds through Venture Financing 100

Padlock Therapeutics Raises Funds through Series A Financing 101

Navitor Pharma Raises USD24 Million in Series A Financing 102

Aduro BioTech Raises USD55 Million in Series C Financing 104

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 106

Assembly Pharma Raises Funds Through Seed Financing 107

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 109

Covagen Raises USD 50.3 Million In Series B Financing 111

Novira Therapeutics Raises USD 28 Million In Series A Financing 113

SutroVax Raises Funds Through Initial Financing Round 115

TopiVert Raises USD28 Million in Venture Financing 116

TopiVert Raises USD 7.4 Million In Venture Financing 118

Pulmocide Raises USD 27.4 Million In Series A Financing 120

Biocartis Raises USD 40.5 Million In Series E Financing 122

Merus Raises USD 42 Million In Extended Series B Financing 124

Rodin Therapeutics Raises Funds Through Seed Financing 126

Vedanta Biosciences Raises Funds Through Venture Financing 127

XO1 Raises USD11 Million in Venture Financing 128

X01 Raises USD 11 Million In Series A Financing 129

Aquinox Pharma Raises USD 18 Million In Series C Financing 130

Biocartis Raises USD 44.7 Million In Series D Financing 132

Genocea Biosciences Raises USD 30 Million In Series C Financing 134

Aragon Pharma Raises USD 50 Million In Series D Financing 137

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 138

Celladon Raises Additional USD 10 Million In Series D Financing 140

Aragon Pharma Raises USD 42 Million In Series C Financing 143

Biocartis Secures USD 96 Million In Series C Financing Round 144

Novira Therapeutics Secures USD 1 Million In Second Round Of Seed Financing 146

Spinal Modulation Secures USD 30 Million In Series D Financing 148

Genocea Biosciences Secures USD 35 Million In Series B Venture Financing 150

PhaseBio Pharma Secures USD 15 Million In The Second Tranche Of Series B Financing Round 153

Covagen Secures USD 6.28 Million In Series A Financing Round 155

Syntaxin Secures USD 29 Million In Series C Financing Round 157

Corimmun Secures USD 10.35 Million In Second Round Of Financing 160

Aquinox Pharma Raises USD 25 Million In Series B Financing 162

Aragon Pharma Raises USD 22 Million In Series B Financing 164

Biocartis Secures USD 41.3 Million In Series B Financing Round 165

Water Street Healthcare Partners Acquires OraPharma 167

Janssen Amends Licensing Agreement with Gilead for STR 169

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 170

Kuros Biosurgery Enters Into Licensing Agreement With Ethicon 172

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 173

Amyris Enters into Research Agreement with Janssen Biotech 174

Janssen Research & Development Enters into Agreement with Genentech 175

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 176

DiamiR Enters into Research Agreement with Janssen Pharma 177

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 178

Janssen Biotech Enters into Agreement with HUB foundation 179

Janssen Pharma Enters into Agreement with University of Pennsylvania 180

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 181

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 182

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 183

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 184

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 185

Janssen Pharma Enters into Agreement with University of California, San Diego 186

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 187

Johnson & Johnson Consumer Enters into Agreement with BioMed X 188

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 189

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 190

Janssen Biotech Enters into Agreement with Eureka Therapeutics 191

Intrexon Enters into Research Agreement with Janssen Pharma 192

Cypralis Enters into Research Agreement with Janssen Pharma 193

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 194

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 195

Nuevolution Enters into Discovery Agreement with Janssen Biotech 196

enGene Enters into Agreement with Janssen Biotech 197

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 198

BlinkBio Enters into Discovery Agreement with Janssen Pharma 199

UbiVac Enters into Agreement with Janssen Biotech 200

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 201

Nextera Enters into Research Agreement with Janssen Biotech 202

Janssen Pharma Terminates Co-Development Agreement with Hutchison MediPharma 203

Janssen Cilag Enters into Agreement with UniQuest 204

Johnson & Johnson Enters into Agreement with University of the Witwatersrand 205

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 206

Janssen Biotech Enters into Research Agreement with Emulate 207

Johnson & Johnson Innovation Partners with Lead Discovery Center 208

AC Immune Enters into Research Agreement with Janssen Pharma 209

X-Chem Enters into Agreement with Janssen Biotech 210

Vectura Enters into Development and License Agreement with Janssen Biotech 211

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 212

Sevion Therapeutics Enters into Discovery Agreement with CNA Development 213

Atreca Enters into Research Agreement with Janssen Biotech 214

Vaccinex Enters into Research Agreement with Janssen Research & Development 215

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 216

Saniona Extends R&D Agreement with Janssen Pharmaceutica 217

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 218

Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 219

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 220

Alector Enters Into Research Agreement With Janssen Pharma 221

Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 222

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 223

Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 225

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 226

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 228

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 229

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 230

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 231

Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 232

Open Monoclonal Expands Agreement with CNA Development 233

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 234

Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 235

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 236

ex scientia Enters into Agreement with Janssen Research & Development 238

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 239

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 241

Johnson & Johnson, Key Competitors 564

Johnson & Johnson, Key Employees 565

Johnson & Johnson, Subsidiaries 567

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Johnson & Johnson, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com